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The familial form of nonmedullary thyroid carcinoma (NMTC) is a complex genetic disorder characterized by
multifocal neoplasia and a higher degree of aggressiveness than its sporadic counterpart. In a large Tasmanian
pedigree (Tas1) with recurrence of papillary thyroid carcinoma (PTC), the most common form of NMTC, an
extensive genomewide scan revealed a common haplotype on chromosome 2q21 in seven of the eight patients with
PTC. To verify the significance of the 2q21 locus, we performed linkage analysis in an independent sample set of
80 pedigrees, yielding a multipoint heterogeneity LOD score (HLOD) of 3.07 ( ), nonparametric linkageap 0.42
(NPL) 3.19, ( ) at marker D2S2271. Stratification based on the presence of at least one case of the follicularPp .001
variant of PTC, the phenotype observed in the Tas1 family, identified 17 such pedigrees, yielding a maximal HLOD
score of 4.17 ( ) and ( ) at markers AFMa272zg9 and D2S2271, respectively.ap 0.80 NPLp 4.99 Pp .00002
These results indicate the existence of a susceptibility locus for familial NMTC on chromosome 2q21.
Nonmedullary thyroid carcinoma (NMTC [MIM acces-
sion number 188550]) is the most common form of thy-
roid cancer, accounting for as many as 90% of all pa-
tients (Schlumberger 1998). The familial form of NMTC
(FNMTC) is increasingly recognized as a distinct clinical
entity, characterized by multifocality and a higher degree
of aggressiveness and mortality with respect to its spo-
radic counterpart (Grossman et al. 1995). The majority
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of FNMTC pedigrees are small in size and may present
with a variety of additional benign common thyroid dis-
orders such as goiter (Lesueur et al. 1999).
Two loci predisposing to FNMTC have been previ-
ously identified: TCO (MIM accession number 603386)
on 19p13.2, in a French family with an unusual form
of NMTC with cell oxyphilia (Canzian et al. 1998), and
PRN1 (MIM accession number 605642) on 1q21, in a
U.S. family with the most common from of NMTC,
papillary thyroid carcinoma (PTC), and papillary renal
neoplasia (Malchoff et al. 2000). However, neither of
these loci, nor the MNG1 (MIM accession number
138800) locus on 14q, identified in a large Canadian
family with multinodular goiter and low recurrence of
NMTC (Bignell et al. 1997), accounts for a significant
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Figure 1 Haplotypes of the eight Tasmanian individuals with PTC. One additional individual affected with neoplastic disease (follicular
adenoma) carries the affected haplotype (shown in generation 4 of the pedigree).
Table 1
Description of the NMTC Consortium Family Set Used in
This Study
No. of
NMTC
Patients
per Family
NMTC Seta fvPTC Subset
No. of
Families
No. with
BTDb
No. of
Families
No. with
BTDb
2 57 14 9 4
3 17 4 5 2
4 4 3 1 1
5 2 2 2 2
Total 80 23 17 9
a The complete family set consists of 191 NMTC patients
with available DNA (average 2.4 cases/family) and an ad-
ditional 38 patients with benign thyroid disease.
b No. of families with at least one additional member af-
fected with benign thyroid disease (BTD).
fraction of FNMTC pedigrees (Lesueur et al. 1999; au-
thors’ unpublished data).
Through the International Consortium for the Ge-
netics of FNMTC, 225 pedigrees have been collected,
81 of which are informative for linkage, with at least
one case of PTC and no cell oxyphilia (Canzian et al.
1998) or renal cancer (Malchoff et al. 2000). Blood sam-
ples and family histories were obtained from family
members after informed consent. DNA was extracted
using a cell lysis and precipitation method (Puregene kit;
Gentra Systems). The protocol for the study was ap-
proved by the French Committee for Protection of Per-
sons in Biomedical Research. For one large Tasmanian
family (Tas1) (Burgess et al. 1997; McKay et al. 1999)
with recurrence of PTC, an extensive genomewide scan,
using a panel of 471 fluorescently labelled microsatellite
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Table 2
Liability Classes Based on Estimates of NMTC
Risk and Goiter Disease Prevalence in the
Tasmanian Population
Category AA Aa aa
Cancer:
In males .001 .05 .05
In females .002 .1 .1
Follicular adenoma .05 .4 .4
Goiter:
In females aged:
!30 years .1 .3 .3
30–50 years .15 .375 .375
51–70 years .2 .4 .4
170 years .25 .375 .375
In males aged:
!30 years .03 .09 .09
30–50 years .05 .125 .125
51–70 years .07 .14 .14
170 years .1 .15 .15
NOTE.—AA p wild type; Aa/aa p affected.
Table 3
Multipoint HLOD Scores for 2q21 According to Phenotypic Breakdown
Phenotypic Category
No. of
Families HLOD
Estimated
Proportion
with Linkage
NPL Score
(P Value)
Position of
Maximum
HLOD
All families: 80 3.07 .42 3.19 (.001) D2S2271
Cancer-only model 2.34 .42 2.53 (.006)
fvPTC: 17 4.17 .80 4.61 (.00006)a AFMa272zg9
Cancer-only model 3.04 .80 3.66 (.0003)a
PTC only: 48 .52 .38 1.46 (.07) D2S2224
Cancer-only model .34 .35 1.27 (.1)
Unknown histopathology 15 0 0 .08 (.5)
a NPL and P values at marker AFMa272zg9 (the point of maximum HLOD score). Using the 17
families, the maximal NPL score was 4.99 ( ); for the cancer-only model, NPL score 4.40Pp .00002
( ) was achieved at marker D2S2271.Pp .00003
markers at an average resolution of 7.6 cM, was com-
pleted on a 377 automated sequencer (PE/ABI). Subse-
quent linkage analysis did not reveal an area of signif-
icant linkage either when all individuals with benign
thyroid disorders were considered affected, as in previ-
ous studies (Bignell et al. 1997; Canzian et al. 1998;
Malchoff et al. 2000) or when individuals with neo-
plastic disease only were considered affected. However,
the reconstruction of haplotypes on chromosome 2q21
showed that seven of eight patients with PTC shared a
common haplotype extending fromD2S436 toD2S1399
(33.8 cM; see fig. 1), with a maximum multipoint LOD
score of 1.28 observed for marker D2S1260, using the
VITESSE program (O’Connell and Weeks 1995).
Since no other comparable region of linkage or co-
segregating haplotype was identified in the Tas1 family,
the relevance of this 2q21 locus to FNMTC was tested
using 80 additional informative FNMTC pedigrees, for
a total of 191 NMTC patients (table 1) collected by the
International Consortium for the Genetics of NMTC.
Using 80 families as an independent family set, we gen-
otyped 13 microsatellites located on 2q21 (D2S436–
11.6 cM–D2S2265–0.57 cM–D2S2224–2.3 cM–
D2S1328–1.0 cM–D2S2271–0.9 cM–D2S2215–
3.4 cM–D2S1260–4.5 cM–AFMa272zg9–0.8 cM–
D2S2256–1.0 cM–D2S114–2.2 cM–D2S1334–1.2
cM–D2S2196–1.2 cM–D2S442). Genetic distances
were taken from the Marshfield genetic maps (Broman et
al. 1998) or the Genetic Location Database (Collins et al.
1996), and the order was confirmed using the BAC fin-
gerprint map. Allele frequencies were calculated from the
data set, using an individual chosen from each family at
random. Linkage analysis was performed using the Gene-
hunter plus (v. 1.2) program package (both parametric
and NPL) (Kruglyak et al. 1996; Kong and Cox 1997),
based on an autosomal dominant model with the disease-
allele frequency fixed at .001. The model incorporated
different probabilities of disease in noncarriers according
to sex-specific rates for NMTC risk (Parkin et al. 1997),
familial relative risk (Goldgar et al. 1994), and age- and
sex-specific rates for goiter based on estimates of goiter
prevalence from Tasmania (table 2). These estimates were
taken from an area of high endemicity (Tasmania) (Gib-
son 1995; Richards 1995), to ensure that any environ-
mental effect on the linkage results is minimized. The
linkage analysis of the 80 FNMTC pedigrees achieved a
maximum multipoint heterogeneity LOD (HLOD) score
of 3.07 at marker D2S2271 ( ; 95% confidenceap 0.42
interval [CI] 0.15–0.70), supporting the notion of an
NMTC susceptibility gene on 2q21 (table 3, fig. 2).
Stratification by histological subtype has been previ-
ously used for genetic studies of FNMTC. Stratification
for the cell oxyphilia phenotype observed in the tumors
of the original TCO family (Canzian et al. 1998; Harach
et al. 1999) confirmed linkage to chromosome 19 (Al-
sanea and Clark 2001; authors’ unpublished data). In
contrast, large unstratified FNMTC family sets do not
support linkage at this locus (Lesueur et al. l999). Similar
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Figure 2 Multipoint HLOD and NPL scores across 2q21, using the complete set of 80 families and the 17 families with at least one case
of fvPTC (with heterogeneity held at 0.42 and 0.80, respectively).
studies of testicular cancer and multinodular goiter have
used stratification by clinical criteria to detect areas of
linkage (Bignell et al. 1997; Neumann et al. 1999; Rap-
ley et al. 2000). A review of the histopathology from
the Tas1 family revealed that at least four of the eight
PTC patients presented with the follicular variant of PTC
(fvPTC) (Burgess et al. 1997; authors’ unpublished
data), a recognized histological subtype (Hedinger et al.
1988). In a recent survey of thyroid carcinoma in Tas-
mania in a 21-year period (1978–1998), fvPTC ac-
counted for only 8% of PTC (Burgess et al. 2000). The
probability of observing four (or more) follicular vari-
ants of eight PTCs in one family, by chance, is low
( , assuming a binomial distribution withPp .002 pp
). By stratifying the 80 FNMTC families according.08
to the presence of at least one case of fvPTC, we iden-
tified 17 families that satisfied this criterion. The analysis
of this subset of families for the 2q21 region resulted in
an HLOD of 4.17 ( ; 95% CI 0.35–1.0) atap 0.80
marker AFMa272zg9, indicating the existence of an
FNMTC susceptibility locus in this region (see table 3
and fig. 2 for summary of LOD scores; see fig. 3 for
segregating haplotypes in the three largest families).
To avoid overreliance of the LOD score on the as-
sumed genetic model, we performed nonparametric link-
age analysis. The 80 unstratified families and the 17
families selected for the presence of a case of fvPTC
achieved a maximum NPL score of 3.19 ( ) andPp .001
an NPL of 4.99 ( ), respectively, at markerpp .00002
D2S2271. These results confirm the parametric linkage
analysis, indicating the presence of strong linkage to this
region (see table 3 and fig. 2 for summary ofNPL scores).
Additional analysis was performed, using only those in-
dividuals with neoplastic disease (table 3). Using this
more conservative cancer-only model, the HLOD scores
decreased in all cases. However, the proportion of fam-
ilies with linkage remained constant, indicating that this
latter result is due to loss of power caused by the ex-
clusion of the informative individuals, as opposed to a
large effect caused by possible phenotype misclassifica-
tion among individuals with benign thyroid disorders.
Informative recombinations among the 17 families that
include a case of fvPTC define a critical region of 5.3
cM from D2S1260 and D2S2256.
Contrary to previous studies (Bignell et al. 1997; Can-
zian et al. 1998; Malchoff et al. 2000), linkage in the
Tas1 family was not found when individuals affected
with nonneoplastic thyroid disease were included in the
analysis. However, this is not surprising, considering that
the level of goiter in the average population is estimated
to be as much as 30% in Tasmania, probably because
of environmental conditions (Gibson 1995; Richards
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Figure 3 Haplotypes of the three largest pedigrees. The recombinations shown in family 225 allow the exclusion of the Pax8 gene, which
has been implicated in NMTC.
1995). It is also of interest that the Tas1 family contains
a member who does not share the affected haplotype
and yet presents with PTC. The distances betweenmark-
ers D2S1260 and D2S2256, identified as the critical re-
gion, make a double recombination event unlikely. Al-
ternatively, this person may represent a phenocopy.
However, the Tasmanian population does not present
with an unusually high level of PTC (Parkin et al. 1997),
and this patient, who does not have a history of irra-
diation, presented at an early age (24 years) with the
rare form of follicular variant and multifocal disease. In
addition, she has a daughter affected with benign thyroid
disease. Taken together, these considerations make a
phenocopy unlikely. As an alternative to the phenocopy
hypothesis, it is possible that the NMTC in this family
is caused by multiple environmental and genetic causes
that cannot be thoroughly identified yet. Interestingly, a
recent study of prostate cancer identified families in
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which a haplotype did not segregate in all affected in-
dividuals, and yet a potential susceptibility gene was
identified (Tavtigian et al. 2001).
Loss of heterozygosity and cytogenetic studies have
implicated 2q, and specifically 2q21, in NMTC (Sozzi
et al. 1992; Roque et al. 1995; Zedenius et al. 1995;
Tung et al. 1997; Bol et al. 1999; Tallini et al. 1999)
and in other forms of cancer (Richter et al. 1997; Sar-
etzki et al. 1997; Piao et al. 2001), suggesting the ex-
istence of one or more tumor suppressors in this region.
Several candidate genes exist in this region, such as
ACVR2, which has been implicated in thyrocyte growth
(Franzen et al. 1999);RAB6/RALB,members of theRas-
like family (Hsieh et al. 1990; Rousseau-Merck et al.
1991); and the LRP-DIT tumor suppressor (Liu et al.
2000). The Pax8 gene, which has been found translo-
cated in NMTC (Kroll et al. 2000), should be excluded
by recombinations in family 225 (fig. 3) and in other
families (data not shown), since it is situated centromeric
to marker D2S2265.
In summary, our data provide evidence in favor of the
existence of a susceptibility locus for FNMTC at 2q21.
This locus appears particularly relevant to—although
not confined to—families with at least one case of
fvPTC. Considering that this locus appears significant
in a larger proportion of FNMTC, identification of crit-
ical recombinations should further define the 2q21 re-
gion and facilitate the positional cloning of the predis-
posing gene.
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